HAVCR2 and cancer: With the development of T cells for cancer immunotherapy, researches have revealed other immune checkpoints that significantly suppress the immune response, such as lymphocyte-activation gene 3 (LAG3), T-cell immunoglobulin mucin 3 (TIM3), and V-domain Ig suppressor of T cell activation (VISTA) [43–45].